Investing.com - Allogene Therapeutics (NASDAQ: ALLO) reported third quarter EPS of $-0.37, $0.15 better than the analyst estimate of $-0.52. Revenue for the quarter came in at $43K versus the consensus estimate of $14.46K.
Allogene Therapeutics's stock price closed at $2.97. It is down -35.29% in the last 3 months and down -68.91% in the last 12 months.
Allogene Therapeutics saw 8 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Allogene Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Allogene Therapeutics's Financial Health score is "weak performance".
Check out Allogene Therapeutics's recent earnings performance, and Allogene Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar